drugset / Trial / NCT03780959

Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)

NCT03780959

Phase 2/3 Completed 69 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study was to determine the efficacy of etanercept in children with polyarticular course JRA.

Timeline

Start
1997-05-01
Primary completion
1998-07-08
Completion
1998-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 0.4 mg/kg Subcutaneous